Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- 3 Mega Pharma-Drugs Now Approved in Japan with Continuous Manufacturing, Japan Players Could Follow Suit Soon: PMDA Specialist
October 19, 2020
- Sakigake-Designated HAE Med Berotralstat, AZ’s Acalabrutinib Up for PAFSC Review on Oct. 30
October 19, 2020
- Japan’s Conditional Approval System for Regenerative Meds Is “Patient-Centered System”: PMDA Exec
October 19, 2020
- Japan Needs to Consider Legal Positioning of Stable Drug Supply Rules: Official
October 19, 2020
- LDP’s Health Committee OKs Bill to Amend Immunization Act
October 16, 2020
- Forxiga’s Heart Failure Use Up for PAFSC Discussion on October 29
October 16, 2020
- PMDA Gets Nearly 10 Requests for Free COVID-19 Vaccine Consultations in 2 Weeks
October 15, 2020
- MHLW to Make “Comprehensive Decision” on Off-Year Drug Pricing Plan: Minister
October 15, 2020
- MHLW Revises Leaflets on HPV Vaccination, Issues Related Notification
October 13, 2020
- Make Temporary Measure Permitting Telemedicine Permanent: Reform Panel Members
October 12, 2020
- MHLW to Reexamine Whether to Permit Sale of Emergency Contraceptives Without a Prescription
October 12, 2020
- Opdivo under PMDA Risk Review for Fulminant Hepatitis
October 12, 2020
- List of MOF’s Proposals Related to Pharmaceuticals
October 9, 2020
- MOF Calls for Setting New Targets for Generic and Biosimilar Use
October 9, 2020
- MHLW to Revise Immunization Act to Allow Govt to Shoulder Liability Risks for COVID-19 Vaccines
October 9, 2020
- MOF Pitches Off-Year Re-Pricing for “All Products” Including Patented Meds, Eyes Adjustment Rate Revision Too
October 9, 2020
- CEFP Members Call for Tapping CPTPP Trade Deal for Joint Drug Manufacturing
October 8, 2020
- Elite Team Working to Secure COVID-19 Vaccines; Indemnity to Be a Major Focus: Ex-MHLW Chief Medical Officer
October 8, 2020
- Japan’s COVID-19 Vaccine, Drug Development Lack Speed: Ex-MHLW Chief Medical Officer
October 7, 2020
- Health Minister Denies November Plan for Avigan's COVID-19 OK
October 7, 2020
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…